Featured in this post are the phosphatidylinositol-3-kinase (or PI3K) inhibitors. Featured drugs include IPI-145 (Infinity Pharmaceuticals $INFI, BYL719 and BKM120 (Novartis $NVS), idelalisib (a.k.a. GS-1101, CAL-101; Gilead Sciences $GILD via Calistoga Pharma), and SAR245409 (Sanofi $SNY). Thanks to @zDonShimoda for compiling this list and allowing me to share it with you. You can find similar compilations related to ALK and HSP90 inhibitors.
Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study.
Ana M. Gonzalez-Angulo, MD, MSc
Poster Board: #19
A phase Ib safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib (gef) in EGFR TKI-resistant NSCLC.
Daniel S. Tan, BSc, MBBS, MRCP
12:00 PM - 12:15 PM
Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL).
Stephen E. Spurgeon, MD
11:30 AM - 11:45 AM
Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory lymphoma.
Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM).
Patrick Y. Wen, MD
Poster Board: #4
Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.
Rebecca S. Heist, MD
Poster Board: #18
Patterns of metastasis and survival in patients with PI3K pathway-driven stage IV squamous cell lung cancers (SQCLC).
Paul K. Paik, MD
Poster Board: #11
12:30 PM - 12:45 PM
Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL).
PI3K pathway as a major determinant of resistance to HER2-targeted therapy in advanced gastric cancer.
Hyo Song Kim, MD
Effective monotherapy despite intratumor heterogeneity: Clonal convergence within the PI3K pathway and sensitivity to mTOR inhibitors in patients with advanced renal cell carcinoma (RCC).
12:15 PM - 12:30 PM
Clinical Development of Novel Agents Targeting the B-Cell Receptor Pathway
Michael E. Williams, MD